CTLA4 and Autoimmunity: This case emphasizes the significance of concurrent administration of antithyroid medication alongside CTLA-4 suppression therapy to mitigate the risk of developing autoimmune disorders.[76] A 51-year-old man who was under treatment with nivolumab for metastatic non-small cell lung cancer presented palpitations, heat intolerance, and insomnia after his fourth infusion.